Cite

HARVARD Citation

    Cosnes, J. et al. (2016). Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease. Alimentary pharmacology & therapeutics. 44 (10), pp. 1102-1113. [Online]. 
  
Back to record